Who makes SYN-020 Delayed Release Capsule?

SYN-020 Delayed Release Capsule is developed by Theriva Biologics, Inc..

What development phase is SYN-020 Delayed Release Capsule in?

SYN-020 Delayed Release Capsule is in Phase 1.

Last reviewed 2026-04-19 · How we verify

SYN-020 Delayed Release Capsule

Theriva Biologics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	SYN-020 Delayed Release Capsule
Also known as	Intestinal Alkaline Phosphatase
Sponsor	Theriva Biologics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Pharmacokinetics, Safety, and Tolerability of SYN-020 (PHASE1)
Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered SYN 020 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SYN-020 Delayed Release Capsule CI brief — competitive landscape report
SYN-020 Delayed Release Capsule updates RSS · CI watch RSS
Theriva Biologics, Inc. portfolio CI